Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C975
http://purl.obolibrary.org/obo/NCIT_C975
|
|---|---|
| Preferred Name | Afimoxifene |
| Definitions |
A tamoxifen metabolite with both estrogenic and anti-estrogenic effects. Afimoxifene has a higher affinity for the estrogen receptor than tamoxifen, and functions as an antagonist in breast cancer cells.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A tamoxifen metabolite with both estrogenic and anti-estrogenic effects. Afimoxifene has a higher affinity for the estrogen receptor than tamoxifen, and functions as an antagonist in breast cancer cells. |
|---|---|
| prefLabel | Afimoxifene
|
| label | Afimoxifene
|
| CHEBI_ID | CHEBI:44616
|
| PDQ_Closed_Trial_Search_ID | 371709
|
| code | C975
|
| Has_Target | |
| prefixIRI | NCIT:C975
|
| in_subset |
See more
See less
|
| Display_Name | Afimoxifene
|
| Preferred_Name | Afimoxifene
|
| FDA_UNII_Code | 17197F0KYM
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Afimoxifene
|
| CAS_Registry |
68047-06-3
68392-35-8
|
| NCI_Drug_Dictionary_ID | 371709
|
| Legacy Concept Name | _4-Hydroxy-Tamoxifen
|
| type | |
| ALT_DEFINITION | A form of the drug tamoxifen that is made by the body after taking tamoxifen. It can also be made in the laboratory, and may help decrease breast density. A topical form of 4-hydroxytamoxifen is being studied in breast cancer screening.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 371709
|
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C2347999
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |